## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.9% below STRENGTH zone (3.0-6.0%); PEG 1.71 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.16)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Dental Equipment & Technology Q3 Earnings: Envista (NYSE:NVST) Simply the Best**
- Source: TradingView â€” Track All Markets | 20260101T110919 | Bullish | Relevance: 76%
- Envista Holdings (NYSE:NVST) delivered the strongest Q3 performance among tracked dental equipment and technology stocks, beating analyst revenue estimates significantly and achieving the fastest revenue growth. Henry Schein (NYSE:HSIC) and Align Technology (NYSE:ALGN) also reported strong quarters, with their stocks rising after earnings. Dentsply Sirona (NYSE:XRAY), however, had the weakest performance with declining revenues and missed EPS guidance.

**2. Dental Implants Market Booming with Rapid Growth Through 2032 |**
- Source: openPR.com | 20260102T110900 | Somewhat-Bullish | Relevance: 62%
- The dental implants market is projected to grow from USD 5.54 billion in 2025 to USD 9.07 billion by 2032, exhibiting a CAGR of 7.3%. This growth is driven by rapid innovation, rising investment, and shifting regional dynamics. The market research report provides insights into market segmentation, competitive landscape, and key players like DENTSPLY Sirona and Straumann AG, offering strategic intelligence for decision-makers.

**3. The Truth About Steris plc: Quiet Healthcare Giant or Next Big Stock Glow-Up?**
- Source: AD HOC NEWS | 20260101T070843 | Neutral | Relevance: 62%
- Steris plc is presented as an unassuming but critical player in the healthcare sector, specializing in sterilization and infection control. The article explores whether this "boring-but-profitable" stock is a worthwhile long-term investment, highlighting its stable business model, consistent financial performance, and strong market positioning compared to competitors. It suggests Steris is a "cop" for serious, risk-aware investors seeking stable healthcare exposure rather than volatile, short-term gains.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($0.15M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +3.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.71 elevated, pricing in significant growth expectations. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.3B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 5.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.71 |
| Forward P/E | 14.5 |
| Current P/E | 15.7 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.4% to 0.9% (+3.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.1pp (needs >3.0% for momentum thesis). MRS_5 at 1.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.93% (CS: 55) | Neutral |
| RSI_14 | 60.0 | Neutral |
| MACD Histogram | -0.29 | Bearish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 1.062x | Above |
| vs SMA200 | 1.105x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $76.82
- **Stop Loss:** $74.16 (3.5% risk)
- **Target:** $79.48 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 541
- **Position Value:** $41,559.62
- **Portfolio %:** 41.56%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*